D
Dan Schell
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Jun 3, 2026
The Editors’ Roundtable: A Midyear Look At The 2026 Life Sciences Industry
14:28
14:35
14:51
15:00
15:10
E
14:20Erin HarrisGUEST
So that's, that's what's been going on so far in terms of twen- so far in twenty twenty-six for Cell and Gene.

Dan SchellGUEST
Yeah, I'd say for me, uh, it's what Ray had mentioned earlier about the real-time clinical trials initiative that the FDA just announced.

Dan SchellGUEST
Um, to me, it's probably the biggest thing that's going on now and, you know, essentially you're getting-- You're sending data earlier to the FDA for them to review, and there's a lot of AI involved, cloud infrastructure, things like that, um, automatic extraction from EHRs.

Dan SchellGUEST
So this is exciting because my industry has always been very slow in our development timelines.

Dan SchellGUEST
In fact, the commissioner said forty-five percent of the current timeline is essentially dead time, you know, spent on paperwork and data cleaning and stuff like that.

Dan SchellGUEST
Um, so big advantages, you know, detect safety problems earlier, reduce delays, things like that.
32 MINS LATER
